Dr. David Sugarbaker
--- Page Content ---
Executive Summary
Dr. David J. Sugarbaker stands among the most influential mesothelioma surgeons in American history. At Brigham and Women's Hospital in Boston, he pioneered the extrapleural pneumonectomy (EPP) procedure[1], modified existing lung-removal techniques to optimize them for mesothelioma patients, and developed trimodal therapy—the combination of surgery, chemotherapy, and radiation that became the standard approach for operable mesothelioma.[2] His research demonstrated that this aggressive approach could extend median survival to 35.3 months when combined with intraoperative heated chemotherapy, with half of patients living even longer.[3] In 2002, Sugarbaker founded the International Mesothelioma Program (IMP), creating the world's largest mesothelioma research and treatment initiative. By the time of his death in 2018, he was among the most experienced mesothelioma surgeons in history.[4]
The International Mesothelioma Program brought together five major Boston-area medical institutions—Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, the Boston VA Healthcare System[5], and Harvard School of Public Health—creating an unprecedented concentration of mesothelioma expertise. This collaboration enabled large-scale research studies, clinical trials[6], and training programs that advanced the field worldwide.[7]
Sugarbaker also developed the Brigham staging system for mesothelioma, which helped surgeons identify patients most likely to benefit from aggressive surgical treatment. His work on the "four-gene ratio" diagnostic test opened pathways for personalized treatment planning based on tumor molecular characteristics. The training programs he established have produced a generation of thoracic surgeons who continue his mission of improving outcomes for mesothelioma patients at institutions across the country.[8]
At a Glance
- Nearly tripled survival — Median survival reached 35.3 months under his protocol, compared to 12-18 months with conventional treatment alone
- Created the dominant surgical framework — His extrapleural pneumonectomy refinements became the benchmark that all subsequent mesothelioma surgeries were measured against
- Built the world's largest mesothelioma program — The International Mesothelioma Program united five Boston institutions into a single coordinated research and treatment network
- Turned a death sentence into a treatable disease — Before his work, most surgeons refused to operate on mesothelioma; afterward, aggressive surgery became standard practice at major cancer centers
- Pioneered heated chemotherapy during surgery — His integration of HIPEC directly into the operating room delivered chemotherapy at the moment of maximum effectiveness
- Developed molecular tools for treatment decisions — The four-gene ratio test moved mesothelioma care toward personalized medicine based on each patient's tumor biology
- Created a staging system designed for surgeons — The Brigham staging system specifically addressed which patients could benefit from aggressive resection
- Trained the next generation — Surgeons he mentored now lead mesothelioma programs at institutions across the United States and internationally
Key Facts
| Metric | Finding |
|---|---|
| Signature Procedure | Extrapleural pneumonectomy (EPP) — removal of lung, pleura, pericardium, and diaphragm |
| Treatment Framework | Trimodal therapy — surgery combined with chemotherapy and radiation |
| Best Median Survival | 35.3 months with trimodal therapy plus intraoperative heated chemotherapy |
| Program Founded | International Mesothelioma Program at Brigham and Women's Hospital (2002) |
| Institutional Partners | Brigham and Women's, Dana-Farber, MGH, Boston VA, Harvard School of Public Health |
| Staging Innovation | Brigham staging system — 4-stage classification for surgical candidacy |
| Molecular Diagnostic | Four-gene ratio test for personalized treatment planning |
| Career Span | August 5, 1953 – August 29, 2018 (age 65) |
| Primary Affiliation | Brigham and Women's Hospital, Harvard Medical School |
| Successor | Dr. Raphael Bueno — continued IMP leadership and genomic research |
Who Was Dr. David Sugarbaker and Why Is He Considered a Pioneer?
Dr. David J. Sugarbaker (August 5, 1953 – August 29, 2018) was a thoracic surgeon who dedicated his career to developing surgical treatments for mesothelioma patients who previously had few options.[9] Based at Brigham and Women's Hospital in Boston, Sugarbaker transformed the surgical treatment of this asbestos-related cancer[10] from a largely futile endeavor into a viable therapeutic option for carefully selected patients.
His approach was distinctly aggressive. At a time when many physicians considered mesothelioma surgery pointless, Sugarbaker developed and refined techniques that gave patients fighting chances they otherwise would not have had. His philosophy was that mesothelioma, while challenging, could be controlled in some patients through comprehensive multimodal treatment.[11]
| "Dr. Sugarbaker gave mesothelioma patients hope when they had none. His willingness to operate on patients others had written off—combined with his meticulous research tracking outcomes—created the evidence base that surgery could extend lives. Many of our clients are alive today because of the surgical techniques he pioneered." |
| — Paul Danziger, Founding Partner, Danziger & De Llano |
What Was Extrapleural Pneumonectomy and How Did Dr. Sugarbaker Improve It?
Extrapleural pneumonectomy (EPP) is an aggressive surgical procedure that removes the affected lung, the pleura (lining around the lung), the pericardium (lining around the heart), and the diaphragm.[7] The goal is to remove as much cancer as possible, achieving what surgeons call "complete macroscopic resection."
While EPP existed before Sugarbaker, he significantly refined the procedure. In 1992, the Annals of Thoracic Surgery published his research on overcoming the technical difficulties of EPP through improved operative techniques.[8] His modifications included:
- Improved Patient Selection: Developing criteria to identify patients most likely to benefit
- Refined Surgical Technique: Reducing operative mortality and complications
- Reconstruction Methods: Better approaches to rebuilding the diaphragm and pericardium
- Perioperative Care: Protocols to optimize patient outcomes before and after surgery
| Structure Removed | Rationale |
|---|---|
| Affected Lung | Mesothelioma typically encases the lung |
| Parietal Pleura | Primary site of mesothelioma origin |
| Visceral Pleura | Disease spreads along pleural surfaces |
| Pericardium | Often involved with advanced disease |
| Hemidiaphragm | Frequently invaded by tumor |
| ⚠️ Note on Current Practice: Following the 2011 MARS trial showing that EPP offered no survival benefit in a randomized setting, many centers transitioned to lung-sparing approaches like pleurectomy with decortication (P/D). However, Sugarbaker's research established principles that continue to guide all mesothelioma surgery. |
What Is Trimodal Therapy and Why Did Dr. Sugarbaker Develop It?
Sugarbaker's most significant contribution was developing trimodal therapy—the combination of surgery, chemotherapy, and radiation therapy to maximize survival in patients with operable mesothelioma.[2]
The Trimodal Approach
| Component | Timing | Purpose |
|---|---|---|
| Chemotherapy | Before and/or after surgery | Shrink tumor, kill microscopic disease |
| Surgery (EPP) | Central component | Remove all visible disease |
| Radiation | After surgery | Destroy remaining cancer cells |
Sugarbaker's research demonstrated that combining these treatments achieved better results than any single modality alone. His studies showed that patients receiving intraoperative heated chemotherapy had significantly longer survival than those who did not.[3]
HIPEC Integration
In select patients, Sugarbaker's team added hyperthermic intraoperative chemotherapy—heated chemotherapy solution (42-43°C) circulated through the chest cavity during surgery. This approach achieved the remarkable median survival of 35.3 months, with half of patients living even longer.[3]
| ✅ Survival Achievement: Dr. Sugarbaker's trimodal therapy with HIPEC achieved median survival of 35.3 months—nearly three years—for appropriately selected patients. This represented a dramatic improvement over historical survival of 12-18 months with single-modality treatment. |
What Was the International Mesothelioma Program?
In 2002, Sugarbaker founded the International Mesothelioma Program (IMP) at Brigham and Women's Hospital, creating the world's largest mesothelioma research and treatment initiative.[4]
Collaborating Institutions
The IMP brought together specialists from five Boston-area institutions:
- Brigham and Women's Hospital – Surgical treatment and inpatient care
- Dana-Farber Cancer Institute – Medical oncology and chemotherapy
- Massachusetts General Hospital – Radiation oncology
- Boston VA Health Care System – Veteran care
- Harvard School of Public Health – Epidemiology and research
This unprecedented multidisciplinary collaboration established Boston as the epicenter of mesothelioma research and set the standard for comprehensive cancer care.[12]
| "The International Mesothelioma Program was revolutionary because it recognized that mesothelioma requires expertise across multiple disciplines. Dr. Sugarbaker understood that no single physician or hospital could provide everything these patients need. The collaborative model he created continues to guide how the best cancer centers approach this disease." |
| — Rod De Llano, Founding Partner, Danziger & De Llano |
IMP Contributions
Under Sugarbaker's leadership, the IMP produced numerous advances:[9]
- Tissue Banking: Established protocols that enabled genomic research
- Clinical Trials: Tested innovative therapeutic combinations
- Staging Systems: Developed the Brigham staging system for surgical planning
- Molecular Tools: Created the four-gene ratio test for personalized medicine
- Training Programs: Educated thoracic surgeons who spread these techniques worldwide
What Was the Brigham Staging System?
Dr. Sugarbaker developed the Brigham staging system to identify which patients were appropriate candidates for aggressive surgical intervention.[13]
| Stage | Disease Extent | Surgery Appropriate? |
|---|---|---|
| Stage I | Disease confined to pleura | Yes – Resectable |
| Stage II | Resectable with positive lymph nodes | Yes – Resectable |
| Stage III | Extended locally but technically resectable | Selected cases only |
| Stage IV | Distant metastases or unresectable | No – Not candidates for EPP |
This staging system specifically addressed the question of surgical resectability—helping surgeons determine which patients could benefit from aggressive surgery and which should receive non-surgical treatment.[14]
What Was the Four-Gene Ratio Test?
Sugarbaker's team at the IMP developed the four-gene ratio test, a molecular tool that determines the best mesothelioma treatment options based on a patient's individual genetic characteristics.[7]
This innovation represented an early step toward personalized medicine in mesothelioma care. By analyzing the expression levels of four specific genes in tumor tissue, physicians could better predict:
- How aggressively the cancer might behave
- Which treatments were most likely to be effective
- Whether surgery would likely benefit the patient
The four-gene ratio test demonstrated that not all mesotheliomas are alike and that treatment decisions should be tailored to individual patients.[15]
What Is Dr. Sugarbaker's Legacy?
Dr. David Sugarbaker died on August 29, 2018, at age 65, having transformed mesothelioma treatment from a largely hopeless endeavor into a field where survival could be measured in years rather than months for selected patients.[16]
Immediate Legacy
- Surgical Volume: Among the most experienced mesothelioma surgeons in history
- Training: Educated thoracic surgeons who continue his methods at institutions worldwide
- Research: Published extensively, creating the evidence base for surgical treatment
- Institution Building: The IMP continues operating under Dr. Raphael Bueno's leadership
Lasting Impact
- Multimodal Therapy: The principle of combining treatments remains standard practice
- Personalized Medicine: Molecular testing to guide treatment decisions is now routine
- Surgical Selection: Careful patient selection based on staging continues to guide practice
- Research Infrastructure: Tissue banks and databases support ongoing research
| "Dr. Sugarbaker's greatest gift to mesothelioma patients was proving that survival was possible. Before his work, a mesothelioma diagnosis felt like an immediate death sentence. He showed that with the right treatment approach, patients could live for years—years they otherwise would not have had with their families." |
| — David Foster, Client Advocate, Danziger & De Llano |
How Does Dr. Sugarbaker's Work Connect to Other Mesothelioma Researchers?
Dr. Sugarbaker's contributions exist within a broader ecosystem of mesothelioma research:[15]
- Dr. Paul H. Sugarbaker (unrelated): Pioneered HIPEC for peritoneal mesothelioma
- Dr. Robert Cameron: Championed lung-sparing P/D as alternative to EPP
- Dr. Raphael Bueno: Succeeded Sugarbaker at the IMP, advancing genomic research
- Dr. Paul Baas: Led immunotherapy trials that created non-surgical options
- Dr. Irving Selikoff: Established the asbestos-mesothelioma connection that made treatment possible
Frequently Asked Questions
What type of surgery did Dr. Sugarbaker perform for mesothelioma?
Dr. Sugarbaker specialized in extrapleural pneumonectomy (EPP), which removes the affected lung, the pleura, the pericardium, and the diaphragm. He refined this procedure significantly over his career, improving patient selection criteria and surgical technique to reduce complications and extend survival.[8]
What is trimodal therapy and did Dr. Sugarbaker invent it?
Trimodal therapy combines surgery, chemotherapy, and radiation into a single treatment plan. Dr. Sugarbaker developed and systematized this approach for mesothelioma patients, demonstrating through clinical research that the combination achieved better outcomes than any single treatment alone.[2]
What survival rates did Dr. Sugarbaker achieve?
In his best-performing patient group, Dr. Sugarbaker achieved a median survival of 35.3 months using trimodal therapy combined with intraoperative heated chemotherapy (HIPEC). This represented a dramatic improvement over the historical median of 12-18 months for mesothelioma patients receiving standard treatment.[3]
What was the International Mesothelioma Program?
The International Mesothelioma Program (IMP) was a collaborative initiative founded by Dr. Sugarbaker in 2002 at Brigham and Women's Hospital. It united five Boston-area institutions to create the world's largest mesothelioma research and treatment center. The program continues today under Dr. Raphael Bueno's leadership.[4]
Is extrapleural pneumonectomy still performed today?
EPP is performed less frequently today than during Dr. Sugarbaker's peak years. Following the 2011 MARS trial, many centers shifted toward lung-sparing pleurectomy with decortication (P/D). However, some specialized centers still perform EPP for carefully selected patients, and the surgical principles Sugarbaker established continue to guide all mesothelioma surgery.[1]
Who continued Dr. Sugarbaker's work after his death?
Dr. Raphael Bueno succeeded Sugarbaker as chief of thoracic surgery at Brigham and Women's Hospital and continued leading the International Mesothelioma Program. Dr. Bueno expanded the program's focus to include genomic research and precision medicine approaches to mesothelioma treatment.[15]
What was the Brigham staging system?
The Brigham staging system was a four-stage classification developed by Dr. Sugarbaker to determine which mesothelioma patients were appropriate candidates for surgical resection. It specifically addressed resectability—whether tumors could be completely removed—rather than only measuring disease extent.[13]
Quick Statistics
- 35.3 months — Median survival achieved with trimodal therapy plus HIPEC for selected patients[3]
- 12-18 months — Historical median survival with conventional single-modality treatment, prior to Sugarbaker's trimodal approach
- 5 institutions — Number of Boston-area hospitals collaborating through the International Mesothelioma Program[4]
- 4 structures removed — EPP removes the lung, pleura, pericardium, and hemidiaphragm in a single operation[8]
- 4 stages — The Brigham staging system classified patients into four groups based on surgical resectability[13]
- 4 genes — The molecular ratio test analyzed expression of four genes to guide personalized treatment[7]
- 42-43°C — Temperature of the heated chemotherapy solution used during intraoperative HIPEC[3]
- 2002 — Year the International Mesothelioma Program was formally established at Brigham and Women's Hospital[4]
- 65 years old — Dr. Sugarbaker's age at the time of his death on August 29, 2018[16]
Related Pages
- Extrapleural Pneumonectomy
- Pleurectomy and Decortication
- Mesothelioma Surgery Overview
- Heated Chemotherapy HITHOC and HIPEC
- Dr. Raphael Bueno
- Pleural Mesothelioma
- Mesothelioma Survival Statistics
- Clinical Trials
- Mesothelioma Specialists
- History of Mesothelioma Research
Get Help
If you or a loved one has been diagnosed with mesothelioma, accessing the best possible treatment—including the surgical techniques Dr. Sugarbaker pioneered—can significantly impact survival. You may also be entitled to compensation from the companies responsible for your asbestos exposure.[17]
The experienced mesothelioma attorneys at Danziger & De Llano have helped thousands of families navigate both the medical and legal challenges of a mesothelioma diagnosis. Call (866) 222-9990 for a free consultation.
For help finding a mesothelioma attorney in your area, visit Mesothelioma Lawyers Near Me. For additional patient and family resources, visit Mesothelioma.net.
References
- ↑ 1.0 1.1 Surgery to Treat Cancer, National Cancer Institute
- ↑ 2.0 2.1 2.2 Malignant Mesothelioma Lawyers, Danziger & De Llano
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 Sugarbaker DJ et al. "Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection." J Thorac Cardiovasc Surg. 2013;145(4):955-963. PubMed
- ↑ 4.0 4.1 4.2 4.3 4.4 International Mesothelioma Program Overview, Brigham and Women's Hospital
- ↑ VA Asbestos Exposure, U.S. Department of Veterans Affairs
- ↑ Brigham Mesothelioma Trials, ClinicalTrials.gov
- ↑ 7.0 7.1 7.2 7.3 Mesothelioma Compensation, Danziger & De Llano
- ↑ 8.0 8.1 8.2 8.3 Mesothelioma Surgery, Mesothelioma.net
- ↑ 9.0 9.1 Mesothelioma Diagnosis Guide, Danziger & De Llano
- ↑ Mesothelioma, National Cancer Institute
- ↑ Multimodal Therapy for Mesothelioma, Mesothelioma.net
- ↑ Mesothelioma Treatment Centers, Mesothelioma.net
- ↑ 13.0 13.1 13.2 529-patient EPP cohort study on surgical volume and outcomes, PubMed
- ↑ Mesothelioma Prognosis, Mesothelioma.net
- ↑ 15.0 15.1 15.2 New Mesothelioma Treatments and Research, Mesothelioma.net
- ↑ 16.0 16.1 In Memoriam: David J. Sugarbaker, MD, Texas Heart Institute Journal, 2019
- ↑ What's Your Mesothelioma Case Worth?, Danziger & De Llano
Cite error: <ref> tag with name "pubmed_9869758" defined in <references> is not used in prior text.
Cite error: <ref> tag with name "pubmed_15559059" defined in <references> is not used in prior text.